What do systematic reviews say?

Combination therapy vs alpha‐blocker

• Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  15 studies · 2687 participants
  Very low

Combination therapy vs alpha‐blocker

Combination therapy showed no clear difference in adverse events compared with alpha‐blockers (low certainty).

• Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic… 2021 · Cochrane Headline outcomes only
  RR 1.1 [0.9, 1.34]
  12 studies · 3561 participants
  Low

Combination therapy vs alpha‐blocker

Combination therapy showed no clear difference in AUR compared with alpha‐blockers (low certainty).

• Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic… 2021 · Cochrane Headline outcomes only
  RR 2.03 [0.97, 4.23]
  19 studies · 4669 participants
  Low

Intensification of prophylactic therapy guided by colonoscopy vs intensification guided by clinical recurrence

Intensification of prophylactic therapy guided by colonoscopy showed no clear difference in clinical recurrence ( compared with intensification guided by clinical recurrence (low certainty).

• Colonoscopy‐guided therapy for the prevention of post‐operative recurrence of Crohn’s disease 2020 · Cochrane Headline outcomes only
  RR 0.82 [0.56, 1.18]
  1 study · 174 participants
  Low

Intensification of prophylactic therapy guided by colonoscopy vs intensification guided by clinical recurrence

Intensification of prophylactic therapy guided by colonoscopy may leads to lower endoscopic recurrence ( compared with intensification guided by clinical recurrence (low certainty).

• Colonoscopy‐guided therapy for the prevention of post‐operative recurrence of Crohn’s disease 2020 · Cochrane Headline outcomes only
  RR 0.73 [0.56, 0.95]
  1 study · 174 participants
  Low

Intensification of prophylactic therapy guided by colonoscopy vs intensification guided by clinical recurrence

• Colonoscopy‐guided therapy for the prevention of post‐operative recurrence of Crohn’s disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  504 participants
  Very low

Intensification of prophylactic therapy guided by colonoscopy vs intensification guided by clinical recurrence

• Colonoscopy‐guided therapy for the prevention of post‐operative recurrence of Crohn’s disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 174 participants
  GRADE not reported

Intensification of prophylactic therapy guided by colonoscopy vs intensification guided by clinical recurrence

The review found no eligible studies for this question.

• Colonoscopy‐guided therapy for the prevention of post‐operative recurrence of Crohn’s disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intensification of prophylactic therapy guided by colonoscopy vs intensification guided by clinical recurrence

It is very uncertain whether intensification of prophylactic therapy guided by colonoscopy changes adverse effects ( compared with intensification guided by clinical recurrence (very low certainty).

• Colonoscopy‐guided therapy for the prevention of post‐operative recurrence of Crohn’s disease 2020 · Cochrane Headline outcomes only
  RR 0.78 [0.49, 1.25]
  1 study · 174 participants
  Very low

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) vs no PMRT

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) may leads to lower local and regional recurrence (LRR) compared with no PMRT (low certainty).

• Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes 2023 · Cochrane Headline outcomes only
  HR 0.2 [0.13, 0.33]
  1 study · 552 participants
  Low

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) vs no PMRT

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) probably leads to lower overall survival (OS) compared with no PMRT (moderate certainty).

• Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes 2023 · Cochrane Headline outcomes only
  HR 0.76 [0.6, 0.97]
  1 study · 552 participants
  Moderate

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) vs no PMRT

• Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) vs no PMRT

• Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) vs no PMRT

• Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) vs no PMRT

• Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) vs no PMRT

• Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  This outcome was not reported in either of the trials.
  0 studies
  No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  No randomised or quasi-randomised controlled trials in people with Von Willebrand disease met the inclusion criteria; no eligible VWD trials were identified.
  0 studies
  No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  Only reported in the Walsh (EACA) trial: in none of the 31 included participants was blood transfusion required.
  1 study · 31 participants
  GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  Mean fall in haemoglobin. Forbes (TXA): 1.4 g/100 mL (placebo) vs 0.3 g/100 mL (TXA). Walsh (EACA): 6.3% (placebo, both centres) vs 3.9% and 3.7% (EACA, centres 1 and 2); differences not significant. Reported in…
  2 studies · 59 participants
  GRADE not reported